Company profile for InnoCare Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical stage biopharmaceutical company committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities. Our vision is to become a global biopharmaceutical leader t...
We are a clinical stage biopharmaceutical company committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities. Our vision is to become a global biopharmaceutical leader that develops anddelivers innovative therapies for patients worldwide. We have built a fully integrated platform that covers the entire spectrum of drug discovery and development functionalities.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Building 8, No. 8 Life Science Park Road, Zhongguancun Life Science Park, Chan...
Telephone
Telephone
+86 10 66609999
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/28/3195971/0/en/InnoCare-Announces-First-Patient-Dosed-in-the-Global-Phase-II-Clinical-Trial-of-TYK2-Inhibitor-Soficitinib-for-Treatment-of-Prurigo-Nodularis.html

GLOBENEWSWIRE
27 Nov 2025

https://www.globenewswire.com/news-release/2025/10/31/3178053/0/en/InnoCare-Announces-First-Patient-Dosed-in-Clinical-Trial-of-Novel-ADC-ICP-B794-in-China.html

GLOBENEWSWIRE
30 Oct 2025

https://www.fiercepharma.com/pharma/zenas-makes-big-bet-ms-drug-striking-2b-licensing-deal-innocare

FIERCE PHARMA
09 Oct 2025

https://www.globenewswire.com/news-release/2025/09/08/3145779/0/en/InnoCare-Announces-Approval-of-HIBRUKA-Orelabrutinib-for-the-Treatment-of-Marginal-Zone-Lymphoma-in-Singapore.html

GLOBENEWSWIRE
07 Sep 2025

https://www.globenewswire.com/news-release/2025/08/21/3137226/0/en/InnoCare-Announces-First-Patient-Dosed-in-the-Registrational-Trial-of-BCL2-Inhibitor-Mesutoclax-for-Treatment-of-BTKi-treated-MCL-Patients-in-China.html

GLOBENEWSWIRE
21 Aug 2025

https://www.businesswire.com/news/home/20250819379893/en/InnoCare-Releases-2025-Interim-Results-and-Business-Highlights

BUSINESSWIRE
19 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty